Company Overview

Merit Medical Systems, Inc. is a publicly traded medical device company that designs, manufactures, and markets proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures. The company operates primarily within the medical devices and healthcare technology industries, with a focus on minimally invasive procedures across cardiology, radiology, oncology, critical care, and endoscopy. Its products are typically used in hospital, clinic, and physician office settings, serving healthcare providers rather than end patients directly.

Merit’s core revenue drivers include single-use medical devices such as catheters, guidewires, access systems, drainage products, embolotherapy devices, and procedure-specific kits. The company is known for incremental innovation, cost-effective manufacturing, and rapid product iteration tailored to clinician needs. Founded in 1987, Merit began as a catheter manufacturer and expanded steadily through internal R&D and acquisitions, evolving into a diversified global supplier with a broad procedural portfolio and vertically integrated manufacturing model.

Business Operations

Merit Medical Systems operates through multiple product-focused business units that align with clinical specialties, including Cardiovascular, Peripheral Intervention, Oncology, Endoscopy, and Critical Care. Revenue is generated primarily through the sale of disposable devices and procedure kits, with limited reliance on capital equipment. The company emphasizes in-house design, tooling, and manufacturing, which supports cost control and faster time-to-market compared to peers.

The company maintains domestic and international manufacturing facilities and distribution networks, supporting direct sales in major markets and distributor-based sales in smaller regions. Merit controls a broad range of proprietary technologies, including embolic materials, access and closure systems, and fluid management solutions. It operates through numerous wholly owned subsidiaries and has historically integrated acquired businesses into its existing manufacturing and commercial infrastructure rather than operating them as standalone units.

Strategic Position & Investments

Merit’s strategic direction centers on expanding its presence in higher-growth, higher-acuity interventional markets while maintaining its core strength in high-volume disposable devices. Growth initiatives include targeted acquisitions, internal product development, and geographic expansion, particularly in interventional oncology, electrophysiology support products, and procedure-specific solutions that increase per-case revenue.

The company has completed multiple acquisitions to broaden its technology base and clinical reach, including Becton Dickinson’s soft tissue biopsy business, Biosphere Medical, Brightwater Medical, Vascular Insights, and Cook Medical’s lead management portfolio. These investments reflect a strategy of acquiring established, revenue-generating technologies that can scale within Merit’s manufacturing and distribution platform, rather than early-stage speculative assets.

Geographic Footprint

Merit Medical Systems is headquartered in North America in the United States and operates globally across Europe, Asia-Pacific, Latin America, and the Middle East. The company maintains manufacturing and distribution facilities in the United States, Mexico, Ireland, France, the Netherlands, Switzerland, Brazil, and Singapore, among other locations, supporting both regional demand and global supply chains.

International markets account for a significant and growing portion of Merit’s revenue, with direct sales operations in major developed healthcare markets and distributor relationships in emerging regions. This global footprint provides diversification across healthcare systems and reimbursement environments while supporting long-term international growth.

Leadership & Governance

Merit Medical Systems was founded by Fred P. Lampropoulos, who has played a central role in shaping the company’s culture of operational discipline, vertical integration, and continuous product improvement. The leadership team emphasizes long-term value creation through manufacturing excellence, clinician-focused innovation, and disciplined capital allocation.

Key executives include:

• Fred P. Lampropoulos – Founder, Chairman of the Board, and Chief Executive Officer
• Raul J. Parra – Chief Financial Officer
• Brian G. Lloyd – President
• Rick W. Osguthorpe – Chief Operating Officer
• Elizabeth D. Taylor – Chief Legal Officer and Corporate Secretary

The company operates under a shareholder-aligned governance structure with an emphasis on operational accountability, internal promotion, and conservative financial management, as reflected in its long-tenured executive team and consistent strategic execution.